On Wednesday, Emergent BioSolutions Inc. (NYSE:EBS) said it secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox, and mpox product portfolio. What Happened: The order includes the previously disclosed U.S. government contract modification to procure ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live), as well as CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) contract options exercised in 2023 and 2024. To date, in 2024, nearly $210 million in customer orders have been delivered for ACAM2000 and VIGIV. For the remainder of 2024 a…